Our News

Press Releases & Media

March 25, 2024

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

Read More
March 1, 2024

Tvardi Therapeutics to Participate at the Cowen 44th Annual Health Care Conference

Read More
January 18, 2024

Tvardi Therapeutics Announces Presentation of REVERTLIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium

Read More
November 21, 2023

Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference

Read More
August 31, 2023

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor

Read More
June 22, 2023

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

Read More
May 25, 2023

Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 Inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Read More
February 28, 2023

Tvardi Therapeutics to Participate at the Cowen 43rd Annual Health Care Conference

Read More
February 7, 2023

Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer

Read More

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.

Accept & Close